Categories: News

Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022

NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2021 financial results prior to market open on Wednesday, March 2, 2022. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.

The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free) passcode 3258502. Archived webcasts will be available on Intercept’s website for approximately two weeks.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

CONTACT

For more information about Intercept, please contact:

Investor inquiries:  investors@interceptpharma.com 

Media inquiries: media@interceptpharma.com

Staff

Recent Posts

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

The Company expects that the application for OTC clearance will shortly be followed by pursuit…

2 hours ago

Senator Jon Ossoff and Vision to Learn Founder Austin Beutner Address National Vision Care Crisis Among School Children

More than 3 million public school children lack the glasses they need. Vision To Learn…

2 hours ago

Avinger Announces Pricing of up to $24 Million Public Offering

$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon…

2 hours ago

Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

Clinical trials for AI Nose-powered Ainos Flora device moves forward with 75 meaningful case results,…

2 hours ago